Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer

NCT07177092 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

118

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer
EGFR

Interventions

PROCEDURE: Surgery
DRUG: Osimertinib

Sponsor

Jianxing He